Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
TREM2 is a receptor for lipids expressed in microglia. The R47H variant of human TREM2 impairs ligand binding and increases Alzheimer’s disease (AD) risk. In mouse models of amyloid β (Aβ) accumulation, defective TREM2 function affects microglial response to Aβ plaques, exacerbating tissue damage, whereas TREM2 overexpression attenuates pathology. Thus, AD may benefit from TREM2 activation. Here, we examined the impact of an anti-human TREM2 agonistic mAb, AL002c, in a mouse AD model expressing either the common variant (CV) or the R47H variant of TREM2. Single-cell RNA-seq of microglia after acute systemic administration of AL002c showed induction of proliferation in both CV- and R47H-transgenic mice. Prolonged administration of AL002c reduced filamentous plaques and neurite dystrophy, impacted behavior, and tempered microglial inflammatory response. We further showed that a variant of AL002c is safe and well tolerated in a first-in-human phase I clinical trial and engages TREM2 based on cerebrospinal fluid biomarkers. We conclude that AL002 is a promising candidate for AD therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AL002 (27) is a TREM2-specific monoclonal antibody that activates TREM2 to enhance microglial function, thereby reducing Aβ plaque formation and attenuating neurite dystrophy.474”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [474]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“enhancing TREM2 signaling by TREM2 agonist antibody, direct delivery of the TREM2 gene, or stimulating other pathways to increase TREM2 expression in the brains of AD mice enhanced Aβ phagocytosis and improved cognitive behaviors.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging evidence has shown that TREM2 activation increased Aβ phagocytosis, relieved neuroinflammation, and improved cognitive behavior in AD mouse models.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an AD mouse model, administration of AL002c, a variant of the AL002 antibody, attenuated tau plaques and neurite dystrophy, improved behavior, and reduced microglial inflammation.537”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [537]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The opposite phenotypes observed in PLCG2 KO iMGs and Plcγ2-P522R KI mice also support the notion to therapeutically stimulate TREM2 functions [6, 16, 17, 43].”
From The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions (2020) · cites this paper as [17]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Self-citationDissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
ATP mediates rapid microglial response to local brain injury in vivo
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., Dustin, M. L., & Gan, W.-B. (2005) · Nature Neuroscience · doi:10.1038/nn1472 · Cited by 3,913
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“In this model, plaques become clearly detectable at 3–4 mo of age and continue to grow for several months (Oakley et al., 2006).”
MethodAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Single-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568
Cited by
Items 501–579 of 579
Zhang, L., Liu, S., Zhao, Q., Liu, X.-Y., Liu, T., Zhang, Q., Liu, M.-H., & Zhao, W. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i2.102328
Pharmacochemical Strategies and Advances in Alzheimer's Disease Drug Development
Chen, J. (2025) · Highlights in Science Engineering and Technology · doi:10.54097/qbjryc26
Hernández, A. M., & Aldasoro, M. (2025) · doi:10.60096/fundacionavanza/2002025
Anti-inflammatory and immunomodulating agents
Britten, J. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30008-0.00014-4
Additional file 1 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608512
Additional file 2 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608515
Additional file 10 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608542
Additional file 7 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608530
Eskandari‐Sedighi, G., Crichton, M. C., Zia, S., Gomez‐Cardona, E., Cortez, L. M., Patel, Z. H., Takahashi, K., St. Laurent, C. D., Sidhu, G., Sarkar, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26725883
Takalo, M., Wittrahm, R., Wefers, B., Parhizkar, S., Jokivarsi, K. T., Kuulasmaa, T., Mäkinen, P. M., Martiskainen, H., Wurst, W., Xiang, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12947848
Additional file 5 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608524
Additional file 4 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608521
Additional file 3 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608518
Beckmann, N., Neuhaus, A., Zurbruegg, S., Volkmer, P., Patiño, C., Joller, S., Feuerbach, D., Doelemeyer, A., Schweizer, T., Rudin, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22598837
Takalo, M., Wittrahm, R., Wefers, B., Parhizkar, S., Jokivarsi, K. T., Kuulasmaa, T., Mäkinen, P. M., Martiskainen, H., Wurst, W., Xiang, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12947857
Takalo, M., Wittrahm, R., Wefers, B., Parhizkar, S., Jokivarsi, K. T., Kuulasmaa, T., Mäkinen, P. M., Martiskainen, H., Wurst, W., Xiang, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12947851
Takalo, M., Wittrahm, R., Wefers, B., Parhizkar, S., Jokivarsi, K. T., Kuulasmaa, T., Mäkinen, P. M., Martiskainen, H., Wurst, W., Xiang, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12947854
Gu, D., Wang, L., Zhang, N., Wang, H., & Yu, X. (2024) · Figshare · doi:10.6084/m9.figshare.26575418
Additional file 6 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608527
Additional file 9 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608539
Additional file 8 of Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C.-C., Knight, J., Ikezu, T. C., Kurti, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608536
Stevenson, M. E. (2024) · DigitalGeorgetown (Georgetown University Library)
Re-educating macrophages to activate antitumor immunity: One Clever Immunotherapy
Viitala, M. (2023) · UTUPub (University of Turku)
Ahmed, C. (2024) · IUScholarWorks (Indiana University) · doi:10.7912/psj7-4j53
A Microglia Initiated Target Therapy in Neuroinflammation for Alzheimer’s Patients
Faiza, B. K., Abedi, A., Andrea, O. B. O., Tamar, G., & Chermahini, S. H. (2024) · Journal of Alzheimers Research and Therapy · doi:10.14302/issn.2998-4211.jalr-24-4926
Rola receptora sortującego SorLA w polaryzacji fenotypu mikrogleju w glejaku : praca doktorska
Kamińska, P. (2025) · RCIN (Digital Repository of the Scientifics Institutes) (Institute of Archaeology and Ethnology of the Polish Academy of Sciences)
Yang, D., Wang, S., Lu, Y., Zhu, J., Chen, J., Zhang, B., Cai, H., Teng, B., Wei, R., Cen, Z., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01950-0
Self-citationCui, L., Yue, Z., Sun, C., & Shao, K. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251411528
Experimental Biology and Medicine Volume 251 Issue 1
(2026) · Frontiers Media SA eBooks · doi:10.3389/978-2-8325-7477-5
Targeting neuroinflammation: a critical opportunity in the evolving landscape of neuropharmacology
Sinha, S. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20260448
Kamzina, A. S., Leinenweber, K. E., Ecca, F., Aldabergenova, A., & Huentelman, M. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.25.706648
Introduction to microglial aging and its involvement in neurodegenerative diseases
Ben-Azu, B., Gargus, M., Verkhratsky, A., & Tremblay, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27340-7.00007-3 · Cited by 1
Li, D., Li, Y., Wen, L., Chen, Z., Gao, F., Shen, Y., & Wang, Q. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-026-01593-7
Association of Serum TREM2 with Acute Coronary Syndrome and its Severity: A Cross-sectional Study
Sudharhsan, M., Renuka, P., Vinodhini, V., Vengatesh, M., & Senghor, K. A. A. (2026) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2026/80067.22951
Régulation de la phagocytose microgliale de l’amyloïde-β par le VEGF
Gea, P. D. (2023) · theses.fr (ABES) · doi:10.70675/ea344be6zc0bbz4b3bz9a85z51a1e1f7f2c6
Role of T-cell immunity in the pathophysiology of Alzheimer’s disease and other Tauopathies
Matta, K. (2024) · theses.fr (ABES) · doi:10.70675/cea4fe5ez67c3z4445z92f7z39af62ba059b
Various Immunotherapy and Targeted Therapeutics for Managing Alzheimer’s Disease
Verma, M., & Singh, N. K. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010010
Sun, X., Yang, L., & 王香明 (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s590661
Liu, G., Xie, B., Zhao, J., & Lv, L. (2026) · Acta Neurologica Belgica · doi:10.1007/s13760-026-03065-1
Kong, Z., Shen, L., Ma, D., & Hou, J. (2026) · Clinical and Translational Discovery · doi:10.1002/ctd2.70140 · Cited by 1
Microglia crosstalk with T cells in neurodegenerative diseases: pathogenesis and treatment targets
Chen, G., Zhao, C., Wang, C., Chen, G., Shi, J., & Chen, H. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116781 · Cited by 1
Xu, Y., Patterson, M. T., Chang, M. D., Ahlberg, I. J., Liu, C. P., Roll, C., Hillman, H., Kennedy, A., Schrank, P. R., Stuttgen, G. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.18.726080
Liao, Y., Ye, S., Zhao, L., Zhou, M., Wen, Y., Zhu, Y., Huang, J., 张罗青, Zhang, X., Guo, P., et al. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05925-6
Li, L., Yang, Q., Zhang, H., Qi, Y., Xie, Y., Ding, Z., & Chen, B. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116978
Nowiński, I., Kobryń, P., Ocicki, D., Bojarski, M., Kwiatkowski, M., Musielak, M. F., Kobryń, I., Zybert, A., Borowska, A., & Grabowski, J. (2026) · Journal of Education Health and Sport · doi:10.12775/jehs.2026.92.72503
Oloruntimehin, E. S., & Malogolovkin, A. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135668
The Cellular Mechanisms of Alzheimer's Disease Protection by the PILRA G78R Variant
Cheng, W. (2025) · ScholarsArchive (Brigham Young University)
Wu, X., Zhang, Y., Yang, Q., Xue, L., Guo, Y., Li, L., Liu, C., Jin, M., Pan, G., Men, J., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70567
Xu, Y., Zhang, G., Cui, X., & Sun, L. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1838634
Microglia in Alzheimer’s disease: Insights into disease progression and therapy
Saini, V., Mukherjee, S., Vora, C., Jindal, H., & Jha, H. C. (2026) · Advances in immunology · doi:10.1016/bs.ai.2026.06.004
Chu, M., Tan, M., Gan, X., Cui, S., & Shi, L. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06091-5 · Cited by 2
Kuhnau, L., Jimenez, G. A., Hack, W. R., Varada, S., Gladen-Kolarsky, N., Kim, S., Klein, F., Banerji, T., Quinn, J. F., Scanlan, T. S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.31.741838
Geller, A., Kwon, M. J., Simmons, S., Xu, Q., Martenis, W. E., Doman, J. L., Natarajan, S., Stalnaker, K. J., Zhang, J., Adiconis, X., et al. (2026) · eLife · doi:10.7554/elife.112104.1
Geller, A., Kwon, M. J., Simmons, S., Xu, Q., Martenis, W. E., Doman, J. L., Natarajan, S., Stalnaker, K. J., Zhang, J., Adiconis, X., et al. (2026) · eLife · doi:10.7554/elife.112104
Wen, J., Tang, H., Yang, Q., Ren, Y., Zhao, Y., Wang, L., Huang, J., Li, J., Zi, W., & Yang, Q. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03148-9
Targeting Microglial Receptors for Alzheimer’s Disease: Translational Barriers from Bench to Bedside
Tang, X., Hasan, I., & Xu, J. (2026) · Neuropharmacology and Therapy · doi:10.15212/npt-2026-0008
Xu, L., Zhang, Y., Jiang, L., Xing, J. F., Hu, J., Lan, T., & Ta, G. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1902577
Alzheimer’s Disease in the Era of Geroscience: Mechanisms, Biomarkers, and Therapeutic Prospects
Chmielewski, P. P. (2026) · Cells · doi:10.3390/cells15171599
Context-dependent roles of osteopontin in aging-related neurological disorders
Huang, D., Zhang, Z., & 龚细礼 (2026) · Journal of International Medical Research · doi:10.1177/03000605261476190
Therapeutic potential of immune cells for neurological disorders
David, A., & Priya, J. D. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44631-3.00011-1
Liu, A., Xing, L., Li, J., Gao, W., Yao, M., Song, J., & Li, H. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103352
Zhang, Q., 张柏民, Wang, Y., Wu, Y., Liu, Y., Feng, S., Zhang, C., Cheng, F., Li, C., Wang, Q., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08896-3
Olazabal-Chias, M., Kratochvil, M., & Rojo, A. I. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106258
Jung, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188011
Jeong, H., Kang, Y., Jeong, S., Yoo, J. M., Choi, Y. S., Kwon, S. H., Hwang, H., Nahm, M., & Kim, D. (2026) · Nanomaterials · doi:10.3390/nano16181158
TREM2-directed therapy in Alzheimer’s disease: from therapeutic window to clinical translation
Kuang, Q., Li, S., Huang, W., Kuang, N., Liu, T., Huang, N., Luo, Y., & Huang, J. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1938062
Zrineh, A., Akwan, R., Darawsheh, R., Nasser, A., & Elsharkawy, M. M. (2026) · Clinical Interventions in Aging · doi:10.2147/cia.s639690
Meng, J., Wang, Y., Wang, J., Chen, Y., Zhao, Z., Tang, Z., Cao, J., Zhang, X., Luo, H., 李徽徽, et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71873
Jassaud, M., Ziane-Chaouche, L., Raffo‐Romero, A., Salzet, M., & Duhamel, M. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04576-9
Jeskanen, H. (2026) · UEF eRepo (University of Eastern Finland)
Therapeutic Targeting of Trem2 Signaling in Alzheimer’s Disease: Opportunities and Challenges
Sharma, M., Kumar, N., Uniyal, S., Malviya, T., & Sharma, A. (2025) · Journal of Drug Discovery and Therapeutics
Boddeda, B. V. M. K., Mugada, V., Khan, M., & Yarguntla, S. R. (2025) · Journal of Experimental and Clinical Medicine
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
Human brain cellular xenografts in neuroimmunology and beyond
Fattorelli, N., Martínez‐Muriana, A., Perry, V. H., & Mancuso, R. (2026) · Immunity · doi:10.1016/j.immuni.2026.09.024
Tumor-derived amyloid-β drives TREM2+ macrophages immunosuppression in cholangiocarcinoma
Li, X., Qian, R., Li, Y., Xu, X., Luo, Z., Lin, H., Zhu, G., Wang, G., Gao, Y., Liu, C., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117548
Lipid-immune interplay in chronic inflammatory-based disorders
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8967-0
CD8+ T cells drive neuroinflammation and cognitive decline in Alzheimer’s disease
Xie, Z., Lu, Y., Qiu, Y., Deng, Q., Zhang, J., Zhou, H., & Zhang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1990281
Metadata
- Authors
- Wang, S., Mustafa, M., Yuede, C. M., Salazar, S. V., Kong, P., Long, H., Ward, M., Siddiqui, O., Paul, R., Gilfillan, S., Ibrahim, A., Rhinn, H., Tassi, I., Rosenthal, A., Schwabe, T., & Colonna, M.
- Affiliations
- Washington University in St. Louis (US)
- Alector (United States) (US)
- Corresponding author
- Schwabe, Tina
- Colonna, Marco
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-06-24
- Volume
- 217
- Issue
- 9
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7478730
- OpenAlex
- W3037497912
- Cited by
- 549
- References
- 41
- Citations by year
- 2026: 106 · 2025: 115 · 2024: 101 · 2023: 93 · 2022: 64 · 2021: 52 · 2020: 18
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (RF1AG05148501, R21 AG059176, RF1 AG059082)
- Cure Alzheimer’s Fund
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- TREM2, Alzheimer's disease, microglial proliferation, amyloid plaques, microglial inflammation, transgenic mouse model, single-cell RNA sequencing, cerebrospinal fluid biomarkers, immunotherapy
- MeSH terms
- Alzheimer Disease, Animals, Antibodies, Monoclonal, Anxiety, Blood-Brain Barrier, Disease Models, Animal, Humans, Membrane Glycoproteins, Mice, Inbred C57BL, Mice, Transgenic, Protein Conformation, Receptors, Immunologic, Solubility, Signal Transduction, Biomarkers, Amyloid beta-Peptides, Neurites, Microglia, Cell Proliferation, Osteopontin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.